BiotechTube

ampreloxetine + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Symptomatic Neurogenic Orthostatic Hypotension

Conditions

Symptomatic Neurogenic Orthostatic Hypotension

Trial Timeline

Jan 24, 2019 → Jul 21, 2021

NCT ID
NCT03750552

About ampreloxetine + Placebo

ampreloxetine + Placebo is a phase 3 stage product being developed by Theravance Biopharma for Symptomatic Neurogenic Orthostatic Hypotension. The current trial status is completed. This product is registered under clinical trial identifier NCT03750552. Target conditions include Symptomatic Neurogenic Orthostatic Hypotension.

What happened to similar drugs?

3 of 16 similar drugs in Symptomatic Neurogenic Orthostatic Hypotension were approved

Approved (3) Terminated (4) Active (9)
✅valsartanNovartisApproved
✅MavacamtenBristol Myers SquibbApproved
✅Droxidopa capsules + Placebo capsulesLundbeckApproved
❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
🔄ISV-305Sun PharmaceuticalPhase 3
🔄rabeprazole sodium + PlaceboEisaiPhase 3
🔄Esomeprazole + Matching placeboAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT05696717Phase 3Active
NCT03829657Phase 3Terminated
NCT03750552Phase 3Completed

Competing Products

20 competing products in Symptomatic Neurogenic Orthostatic Hypotension

See all competitors
ProductCompanyStageHype Score
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
ISV-305Sun PharmaceuticalPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40
Verinurad + Febuxostat + DapagliflozinAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
Esomeprazole + Matching placeboAstraZenecaPhase 3
40
DFV890 + PlaceboNovartisPhase 2
35
Omalizumab + Omalizumab + PlaceboNovartisPhase 2
35
Pasireotide + OctreotideNovartisPhase 3
40
TegaserodNovartisPhase 2
35
valsartanNovartisApproved
43
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
26
Epoetin biosimilarPfizerPre-clinical
26
Apixaban + Standard of carePfizerPhase 3
40
Azithromycin plus chloroquinePfizerPhase 3
32
MavacamtenBristol Myers SquibbApproved
50
Aficamten + PlaceboSanofiPhase 3
44
Vandetanib 300 mgSanofiPre-clinical
26
REGN7508 + Acetylsalicylic Acid (ASA) + PlaceboRegeneron PharmaceuticalsPhase 3
47
Rivaroxaban + PlaceboBayerPhase 3
37